Evidence map›Paper›PMID 26810771›Full record

ArticleBMC cancer2016

Gene methylation profile of gastric cancerous tissue according to tumor site in the stomach.

Rita Kupcinskaite-Noreikiene, Rasa Ugenskiene, Alius Noreika, Viktoras Rudzianskas, Jurgita Gedminaite, Jurgita Skieceviciene, Elona Juozaityte

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Journal of Cancer · 2018
    Article
  6. Article
  7. How to stomach an epigenetic insult: the gastric cancer epigenome.Nature reviews. Gastroenterology & hepatology · 2017
    Review
  8. Relationships betweenOncoTargets and therapy · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rita Kupcinskaite-NoreikieneOncology Institute of the Lithuanian University of Health Sciences, Eiveniu 2, Kaunas, 50009, Lithuania. rita.kupcinskaite@gmail.com.
Rasa UgenskieneOncology Institute of the Lithuanian University of Health Sciences, Eiveniu 2, Kaunas, 50009, Lithuania.
Alius NoreikaKaunas University of Technology, Studentu 50, Kaunas, 50009, Lithuania.
Viktoras RudzianskasOncology Institute of the Lithuanian University of Health Sciences, Eiveniu 2, Kaunas, 50009, Lithuania.
Jurgita GedminaiteOncology Institute of the Lithuanian University of Health Sciences, Eiveniu 2, Kaunas, 50009, Lithuania.
Jurgita SkiecevicieneLaboratory of Clinical and Molecular Gastroenterology, Lithuanian University of Health Sciences, Eiveniu 2, Kaunas, 50009, Lithuania.
Elona JuozaityteOncology Institute of the Lithuanian University of Health Sciences, Eiveniu 2, Kaunas, 50009, Lithuania.
Lithuanian University of Health Sciences · LTKaunas University of Technology · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is considerable information on the methylation of the promoter regions of different genes involved in gastric carcinogenesis. However, there is a lack of information on how this epigenetic process differs in tumors originating at different sites in the stomach. The aim of this study is to assess the methylation profiles of the MLH1, MGMT, and DAPK-1 genes in cancerous tissues from different stomach sites.

methodsSamples were acquired from 81 patients suffering stomach adenocarcinoma who underwent surgery for gastric cancer in the Lithuanian University of Health Sciences Hospital Kaunas Clinics in 2009-2012. Gene methylation was investigated with methylation-specific PCR. The study was approved by the Lithuanian Biomedical Research Ethics Committee.

resultsThe frequencies of methylation in cancerous tissues from the upper, middle, and lower thirds of the stomach were 11.1, 23.1, and 45.4%, respectively, for MLH1; 22.2, 30.8, and 57.6%, respectively, for MGMT; and 44.4, 48.7, and 51.5%, respectively, for DAPK-1. MLH1 and MGMT methylation was observed more often in the lower third of the stomach than in the upper third (p < 0.05). In the middle third, DAPK-1 promoter methylation was related to more-advanced disease in the lymph nodes (N2-3 compared with N0-1 [p = 0.02]) and advanced tumor stage (stage III rather than stages I-II [p = 0.05]). MLH1 and MGMT methylation correlated inversely when the tumor was located in the lower third of the stomach (coefficient, -0.48; p = 0.01). DAPK-1 and MLH1 methylation correlated inversely in tumors in the middle-third of the stomach (coefficient, -0.41; p = 0.01).

conclusionGene promoter methylation depends on the gastric tumor location.

Indexed as

Adaptor Proteins, Signal TransducingAdultAgedAged, 80 and overDeath-Associated Protein KinasesDNA MethylationDNA Modification MethylasesDNA Repair EnzymesFemaleHumansMaleMiddle AgedMutL Protein Homolog 1Neoplasm StagingNuclear ProteinsPromoter Regions, GeneticAdaptor Proteins, Signal TransducingDAPK1 protein, humanDeath-Associated Protein KinasesDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanMLH1 protein, humanMutL Protein Homolog 1Nuclear ProteinsTumor Suppressor Proteins

Identifiers

PMID26810771
PMCPMC4727411
OpenAlexW2262185074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.